CytomX Therapeutics, Inc. Aktie News

CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy (28% ORR, up to 43% at highest dose) but presents notable GI toxicity risks requiring close monitoring. Financially, CTMX is well-capitalized with $158.1 million in cash, providing a cash runway i...

It isn't difficult for a modestly priced stock to leap in value on a positive news item. That's the dynamic behind the monster rise these past few days of clinical-stage biotech CytomX Therapeutics (CTMX 17.84%).

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Sean McCarthy - Chairman & CEO Conference Call Participants Ross Cohen Presentation Ross Cohen So really quickly on disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the f...

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.

I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.

CytomX (CTMX) Q2 Revenue Drops 26%